AU2011352801B2 - Compositions and methods for identifying and differentiating viral components of multivalent shipping fever vaccines - Google Patents
Compositions and methods for identifying and differentiating viral components of multivalent shipping fever vaccines Download PDFInfo
- Publication number
- AU2011352801B2 AU2011352801B2 AU2011352801A AU2011352801A AU2011352801B2 AU 2011352801 B2 AU2011352801 B2 AU 2011352801B2 AU 2011352801 A AU2011352801 A AU 2011352801A AU 2011352801 A AU2011352801 A AU 2011352801A AU 2011352801 B2 AU2011352801 B2 AU 2011352801B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- primer
- viral
- dna
- bvdv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 229960005486 vaccine Drugs 0.000 title claims abstract description 66
- 208000008939 Pneumonic Pasteurellosis Diseases 0.000 title claims abstract description 17
- 210000000605 viral structure Anatomy 0.000 title claims abstract description 9
- 239000000523 sample Substances 0.000 claims abstract description 145
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 110
- 230000003612 virological effect Effects 0.000 claims abstract description 93
- 238000001514 detection method Methods 0.000 claims abstract description 84
- 241000700605 Viruses Species 0.000 claims abstract description 75
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 47
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 47
- 239000002157 polynucleotide Substances 0.000 claims abstract description 47
- 241000283690 Bos taurus Species 0.000 claims abstract description 31
- 241000530623 Bovine viral diarrhea virus 2 Species 0.000 claims abstract description 19
- 230000002238 attenuated effect Effects 0.000 claims abstract description 14
- 238000003753 real-time PCR Methods 0.000 claims abstract description 11
- 239000012472 biological sample Substances 0.000 claims abstract description 8
- 230000003321 amplification Effects 0.000 claims description 110
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 110
- 239000002773 nucleotide Substances 0.000 claims description 108
- 125000003729 nucleotide group Chemical group 0.000 claims description 106
- 150000007523 nucleic acids Chemical class 0.000 claims description 92
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 58
- 102000039446 nucleic acids Human genes 0.000 claims description 57
- 108020004707 nucleic acids Proteins 0.000 claims description 57
- 241000711895 Bovine orthopneumovirus Species 0.000 claims description 55
- 238000003556 assay Methods 0.000 claims description 52
- 108020004414 DNA Proteins 0.000 claims description 33
- 239000002245 particle Substances 0.000 claims description 19
- 238000011895 specific detection Methods 0.000 claims description 11
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 claims description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 2
- 230000003362 replicative effect Effects 0.000 claims description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 241000894007 species Species 0.000 abstract description 13
- 229940031348 multivalent vaccine Drugs 0.000 abstract description 9
- 230000002068 genetic effect Effects 0.000 abstract description 5
- 244000144972 livestock Species 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 238000009007 Diagnostic Kit Methods 0.000 abstract description 4
- 206010051511 Viral diarrhoea Diseases 0.000 abstract description 4
- 241000282817 Bovidae Species 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract description 2
- 239000013615 primer Substances 0.000 description 143
- 239000000047 product Substances 0.000 description 46
- 230000036515 potency Effects 0.000 description 30
- 238000003752 polymerase chain reaction Methods 0.000 description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 description 28
- 230000000295 complement effect Effects 0.000 description 26
- 238000003757 reverse transcription PCR Methods 0.000 description 24
- 238000010790 dilution Methods 0.000 description 23
- 239000012895 dilution Substances 0.000 description 23
- 239000002751 oligonucleotide probe Substances 0.000 description 23
- 230000002441 reversible effect Effects 0.000 description 22
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 17
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000000120 cytopathologic effect Effects 0.000 description 16
- 241000710778 Pestivirus Species 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 244000309466 calf Species 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 208000002289 Bovine Respiratory Disease Complex Diseases 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- -1 deoxyribonucleotide triphosphates Chemical class 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000011835 investigation Methods 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 239000002987 primer (paints) Substances 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000004448 titration Methods 0.000 description 8
- 235000011178 triphosphate Nutrition 0.000 description 8
- 239000001226 triphosphate Substances 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 7
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000009260 cross reactivity Effects 0.000 description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000000153 supplemental effect Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 239000003155 DNA primer Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 108010076039 Polyproteins Proteins 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000005547 deoxyribonucleotide Substances 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000005562 infectious bovine rhinotracheitis Diseases 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000379 polymerizing effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 244000052613 viral pathogen Species 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241001118702 Border disease virus Species 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000606831 Histophilus somni Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
- 238000013081 phylogenetic analysis Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 241001137307 Cyprinodon variegatus Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 101000984570 Enterobacteria phage T4 Baseplate wedge protein gp53 Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000997743 Escherichia phage Mu Serine recombinase gin Proteins 0.000 description 1
- 101000830028 Escherichia phage Mu Uncharacterized protein gp25 Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 241001293415 Mannheimia Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- YWMAPNNZOCSAPF-UHFFFAOYSA-N Nickel(1+) Chemical compound [Ni+] YWMAPNNZOCSAPF-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101800001019 Non-structural protein 4B Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 229940124878 RotaTeq Drugs 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 229940124859 Rotavirus vaccine Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010041047 Slow virus infection Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 108700022715 Viral Proteases Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 108700016235 bovine viral diarrhea virus p80 Proteins 0.000 description 1
- 208000000982 bovine virus diarrhea-mucosal disease Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000012677 causal agent Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- SCKNFLZJSOHWIV-UHFFFAOYSA-N holmium(3+) Chemical compound [Ho+3] SCKNFLZJSOHWIV-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006057 immunotolerant effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108010066369 protein p80 Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- DOSGOCSVHPUUIA-UHFFFAOYSA-N samarium(3+) Chemical compound [Sm+3] DOSGOCSVHPUUIA-UHFFFAOYSA-N 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940031418 trivalent vaccine Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061427404P | 2010-12-27 | 2010-12-27 | |
| US61/427,404 | 2010-12-27 | ||
| PCT/US2011/066392 WO2012092054A2 (en) | 2010-12-27 | 2011-12-21 | Compositions and methods for identifying and differentiating viral components of multivalent shipping fever vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011352801A1 AU2011352801A1 (en) | 2013-06-27 |
| AU2011352801B2 true AU2011352801B2 (en) | 2015-05-21 |
Family
ID=45532015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011352801A Ceased AU2011352801B2 (en) | 2010-12-27 | 2011-12-21 | Compositions and methods for identifying and differentiating viral components of multivalent shipping fever vaccines |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9238843B2 (enExample) |
| EP (1) | EP2659007B1 (enExample) |
| JP (1) | JP6027023B2 (enExample) |
| CN (1) | CN103403191B (enExample) |
| AR (1) | AR084358A1 (enExample) |
| AU (1) | AU2011352801B2 (enExample) |
| BR (1) | BR112013016467A2 (enExample) |
| CA (1) | CA2822798C (enExample) |
| ES (1) | ES2613537T3 (enExample) |
| MX (1) | MX348307B (enExample) |
| NZ (1) | NZ611657A (enExample) |
| PL (1) | PL2659007T3 (enExample) |
| PT (1) | PT2659007T (enExample) |
| TW (1) | TWI513821B (enExample) |
| WO (1) | WO2012092054A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109563555A (zh) * | 2016-05-06 | 2019-04-02 | 起源生物织物有限公司 | 培养的皮革及由其制作的产品 |
| CN106906307A (zh) * | 2017-03-10 | 2017-06-30 | 中国农业科学院特产研究所 | 牛副流感病毒3型病毒nano‑PCR检测试剂盒及其制备方法 |
| CN113913461A (zh) * | 2021-11-15 | 2022-01-11 | 贵州大学 | 牛病毒性腹泻e0-e2基因重组腺病毒疫苗构建方法 |
| KR102827389B1 (ko) * | 2021-12-03 | 2025-07-03 | 대한민국 | 소바이러스성설사 바이러스 유전아형 동시감별 진단 키트 및 진단방법 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001039801A2 (en) * | 1999-11-30 | 2001-06-07 | Boehringer Ingelheim Vetmedica Gmbh | Safe attenuated bovine viral diarrhea viruses for use in pregnant cows |
| WO2004073737A1 (en) * | 2003-02-19 | 2004-09-02 | Merial Limited | Vaccination or immunization using a prime-boost regimen against brsv, bhv-1, bvdv, bpi-3 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| DE3329892A1 (de) | 1983-08-18 | 1985-03-07 | Köster, Hubert, Prof. Dr., 2000 Hamburg | Verfahren zur herstellung von oligonucleotiden |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| FR2596761B1 (fr) | 1986-04-08 | 1988-05-20 | Commissariat Energie Atomique | Derives de nucleosides et leur utilisation pour la synthese d'oligonucleotides |
| US4992051A (en) * | 1987-11-03 | 1991-02-12 | Novagene, Inc. | Infectious bovine rhinotracheitis virus mutants, methods for the production of same and methods for the use of same |
| US5491225A (en) | 1991-12-19 | 1996-02-13 | Hoffmann-La Roche Inc. | PCR primers for detection of legionella species and methods for controlling visual intensity in hybridization assays |
| US5279721A (en) | 1993-04-22 | 1994-01-18 | Peter Schmid | Apparatus and method for an automated electrophoresis system |
| EP0968722B1 (en) | 1994-05-10 | 2007-06-20 | Wyeth | Improved modified live BRSV vaccine |
| FR2751229B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
| US20060084052A1 (en) * | 2001-03-27 | 2006-04-20 | Smithkline Beecham Corp. | Detection of viable agents |
| DE60139319D1 (en) * | 2000-06-23 | 2009-09-03 | Intervet Int Bv | Us |
| EP2180064A3 (en) * | 2000-10-18 | 2010-08-11 | Pharmasset, Inc. | Multiplex quantification of nucleic acids in diseased cells |
| PL1727562T3 (pl) | 2004-03-17 | 2008-10-31 | Pharmacia & Upjohn Co Llc | Sposób szczepienia przeciw zakażeniu jąder wirusem BVD |
| US20090068223A1 (en) | 2005-11-15 | 2009-03-12 | Boehringer Ingelheim Vetmedica, Inc. | Combination vaccine comprising an attenuated bovine viral diarrhea virus |
| WO2007094854A2 (en) | 2005-12-14 | 2007-08-23 | The Board Of Regents Of The University Of Oklahoma | Rna virus vaccines and methods |
| US8354514B2 (en) * | 2007-01-12 | 2013-01-15 | Lawrence Livermore National Security, Llc | Multiplex detection of agricultural pathogens |
| CN101696453B (zh) * | 2009-11-02 | 2012-01-25 | 东北农业大学 | 检测牛病毒性腹泻病毒逆转录环介导等温扩增反应试剂盒的制备方法 |
| PT2658570T (pt) * | 2010-12-27 | 2019-02-08 | Elanco Us Inc | Composições e métodos vacinais contra o vírus da diarreia viral bovina tipo 1b |
-
2011
- 2011-12-19 AR ARP110104767A patent/AR084358A1/es unknown
- 2011-12-21 CN CN201180068515.XA patent/CN103403191B/zh not_active Expired - Fee Related
- 2011-12-21 EP EP11813620.9A patent/EP2659007B1/en not_active Not-in-force
- 2011-12-21 PT PT118136209T patent/PT2659007T/pt unknown
- 2011-12-21 JP JP2013547557A patent/JP6027023B2/ja not_active Expired - Fee Related
- 2011-12-21 US US13/995,707 patent/US9238843B2/en not_active Expired - Fee Related
- 2011-12-21 AU AU2011352801A patent/AU2011352801B2/en not_active Ceased
- 2011-12-21 PL PL11813620T patent/PL2659007T3/pl unknown
- 2011-12-21 MX MX2013007586A patent/MX348307B/es active IP Right Grant
- 2011-12-21 CA CA2822798A patent/CA2822798C/en not_active Expired - Fee Related
- 2011-12-21 ES ES11813620.9T patent/ES2613537T3/es active Active
- 2011-12-21 WO PCT/US2011/066392 patent/WO2012092054A2/en not_active Ceased
- 2011-12-21 NZ NZ61165711A patent/NZ611657A/en not_active IP Right Cessation
- 2011-12-21 BR BR112013016467A patent/BR112013016467A2/pt not_active Application Discontinuation
- 2011-12-23 TW TW100148447A patent/TWI513821B/zh not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001039801A2 (en) * | 1999-11-30 | 2001-06-07 | Boehringer Ingelheim Vetmedica Gmbh | Safe attenuated bovine viral diarrhea viruses for use in pregnant cows |
| WO2004073737A1 (en) * | 2003-02-19 | 2004-09-02 | Merial Limited | Vaccination or immunization using a prime-boost regimen against brsv, bhv-1, bvdv, bpi-3 |
Non-Patent Citations (1)
| Title |
|---|
| FULTON, R. W., et al., Journal of the American Veterinary Medical Association, 2006, vol. 228, pages 578-584 * |
Also Published As
| Publication number | Publication date |
|---|---|
| PL2659007T3 (pl) | 2017-08-31 |
| JP6027023B2 (ja) | 2016-11-16 |
| CN103403191B (zh) | 2016-05-18 |
| ES2613537T3 (es) | 2017-05-24 |
| AU2011352801A1 (en) | 2013-06-27 |
| JP2014502846A (ja) | 2014-02-06 |
| MX348307B (es) | 2017-06-06 |
| US20130266934A1 (en) | 2013-10-10 |
| PT2659007T (pt) | 2017-01-18 |
| CA2822798C (en) | 2016-11-01 |
| EP2659007B1 (en) | 2016-11-16 |
| CN103403191A (zh) | 2013-11-20 |
| EP2659007A2 (en) | 2013-11-06 |
| MX2013007586A (es) | 2013-10-17 |
| TW201307571A (zh) | 2013-02-16 |
| BR112013016467A2 (pt) | 2018-09-18 |
| TWI513821B (zh) | 2015-12-21 |
| CA2822798A1 (en) | 2012-07-05 |
| NZ611657A (en) | 2015-04-24 |
| US9238843B2 (en) | 2016-01-19 |
| WO2012092054A3 (en) | 2012-12-27 |
| WO2012092054A2 (en) | 2012-07-05 |
| AR084358A1 (es) | 2013-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Belák | Molecular diagnosis of viral diseases, present trends and future aspects: A view from the OIE Collaborating Centre for the Application of Polymerase Chain Reaction Methods for Diagnosis of Viral Diseases in Veterinary Medicine | |
| Hoffmann et al. | A universal heterologous internal control system for duplex real-time RT-PCR assays used in a detection system for pestiviruses | |
| Teng et al. | Specific detection of reverse transcription-loop-mediated isothermal amplification amplicons for Taura syndrome virus by colorimetric dot–blot hybridization | |
| CN110651051B (zh) | 用于检测巴贝虫的组合物和方法 | |
| US20090226895A1 (en) | Method of detecting vibrio parahaemolyticus via real-time PCR-hybridization | |
| CN111118211A (zh) | 基于环介导等温扩增技术的牛结节性皮肤病检测试剂盒及方法 | |
| AU2011352801B2 (en) | Compositions and methods for identifying and differentiating viral components of multivalent shipping fever vaccines | |
| Lim et al. | Enhanced detection and serotyping of foot‐and‐mouth disease virus serotype O, A, and Asia1 using a novel multiplex real‐time RT‐PCR | |
| CN102747144A (zh) | 三种菌的三重实时荧光pcr检测引物、探针、检测试剂盒和检测方法 | |
| de Arce et al. | A multiplex RT-PCR assay for the rapid and differential diagnosis of classical swine fever and other pestivirus infections | |
| US7582740B2 (en) | Methods and kits for detecting SARS-associated coronavirus | |
| KR102739275B1 (ko) | 돼지열병바이러스의 검출 또는 판별을 위한 조성물 및 방법 | |
| Bohórquez et al. | Development of a new loop-mediated isothermal amplification test for the sensitive, rapid, and economic detection of different genotypes of Classical swine fever virus | |
| KR102435209B1 (ko) | 인플루엔자 a형 및 b형 바이러스와 제2형 중증급성호흡기증후군 코로나바이러스를 구별하여 동시에 검출하기 위한 조성물 및 이를 이용한 검출 방법 | |
| WO2003002766A2 (en) | Method for detection of foot-and-mouth disease virus | |
| RU2739333C1 (ru) | Штамм бактерий Escherichia coli JM 109 4-162 - продуцент рекомбинантной плазмиды pWNV4protC, несущей последовательность участка гена полипротеина West Nile virus 4 генотипа, кодирующего капсидный белок | |
| RU2715625C1 (ru) | Набор олигонуклеотидных праймеров и флуоресцентно-меченого зонда для идентификации вируса западного нила 1 генотипа | |
| CN114395643A (zh) | 非洲猪瘟病毒的双通道数字pcr检测试剂盒及方法 | |
| CN111500774A (zh) | 一种流行性出血病病毒及血清型鉴定rt-pcr试剂盒 | |
| RU2737396C1 (ru) | Набор олигонуклеотидных праймеров и флуоресцентно-меченого зонда для идентификации вируса западного нила 4 генотипа (west nile virus lineage 4) | |
| RU2744096C1 (ru) | Штамм бактерий Escherichia coli JM 109 2-428 - продуцент рекомбинантной плазмиды pWNV2protC, несущей последовательность 5'-нетранслируемой области и участка гена полипротеина West Nile virus 2 генотипа, кодирующего капсидный белок | |
| JPWO2020071419A1 (ja) | ロタウイルスの遺伝子型検出方法と、これに用いる遺伝子増幅用プライマーセット | |
| Krásna et al. | MOL-PCR and xMAP technology–a novel approach to the detection of African swine fever virus DNA | |
| RU2744095C1 (ru) | Штамм бактерий Escherichia coli JM 109 1-430 - продуцент рекомбинантной плазмиды pWNV1protC, несущей последовательность 5'-нетранслируемой области и участка гена полипротеина West Nile virus 1 генотипа, кодирующего капсидный белок | |
| Paraguison et al. | Possible use of RNA isolate from inactivated vaccine for external positive control in reverse transcription-based detection of foot-and-mouth disease virus in bull semen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: ELANCO US INC. Free format text: FORMER OWNER(S): ELI LILLY AND COMPANY |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |